CAV1 and lung carcinoma: Regarding lung cancer, in particular for advanced non-small cell lung cancer (NSCLC), Herrera et al. demonstrated the survival improvement using nab-paclitaxel in combination with carboplatin, especially in Cav-1 positive patients [27].